▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3655 by analyst upside · 2026-09-27
BBNX
Beta Bionics, Inc.
Healthcare · Market Cap $1B · P/E 0x
ANALYST PRICE TARGET
+8.2%
implied upside to consensus target
Current Price $21.51
Consensus Target $23.28
Bull Target $30.4
Bear Target $16.0
Analysts Covering 12
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
7
Hold
4
Sell
0
52-Week Low $8.8
52-Week High $32.71
YTD Return -26.5%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.60
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $119M
Profit Margin -61.3%
52-WEEK RANGE
52-Week Low $8.8
52-Week High $32.71
Current Price $21.51
Bear Target $16.0
Bull Target $30.4
● Now $21.51 ● Target $23.28
TRADING DATA
Avg Volume 1.3M
YTD Return -26.5%
Analyst Count 12
Consensus Buy
Upside to Target +8.2%
Last Updated 2026-09-27

ANALYST SUMMARY

Beta Bionics, Inc. (BBNX) is currently trading at $21.51 with a Wall Street consensus price target of $23.28, implying potential upside of 8.2% over the next 12 months. 12 analysts currently cover BBNX, with a consensus rating of Buy - 67% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $30.4, while the most cautious has a target of $16.0.

BBNX operates in the Healthcare sector with a market capitalisation of $1B. The stock is down 26.5% year-to-date and is currently trading near the upper end of its 52-week range of $8.8 – $32.71.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for BBNX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Truist Securities - Reiterated
Buy → Buy 2026-09-24 Building track record
Wells Fargo ● Initiated
Overweight 2026-09-23 Building track record
B of A Securities - Reiterated
Neutral → Neutral 2026-09-15 Building track record
Truist Securities reit
Buy → Buy 2026-09-15 Building track record
Baird - Reiterated
Neutral → Neutral 2026-09-15 Building track record
Leerink Partners - Reiterated
Outperform → Outperform 2026-09-14 29% win rate (7 calls)
William Blair ● Initiated
Market Perform 2026-08-21 44% win rate (9 calls)
Goldman Sachs - Reiterated
Buy → Buy 2026-07-15 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
51
out of 100
Coverage depth
20/30
Consensus clarity
17/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →